Active ingredient: Agomelatine
Note about medicines names
Most medicines have two names: the active ingredient and the brand name. The active ingredient is the chemical in the medicine that makes it work. The brand name is the name given to the medicine by its manufacturer. There may be several brands that contain the same active ingredient. This website uses active ingredient names (e.g. amoxycillin), with brand names in brackets and with a capital letter (e.g. Amoxil). We also discuss medicines in groups or ‘classes’ when their effects or actions are very similar.
What is agomelatine?
Agomelatine is used to treat depression and some other illnesses. It acts on brain receptors for melatonin, a hormone that is important for regulating sleep, as well as serotonin receptors. Agomelatine is the only antidepressant that acts on melatonin receptors.
Find out more about
- What agomelatine does and how effective it is
- Who agomelatine is for and who should be cautious
- Side effects of agomelatine
- Interactions with agomelatine
- Brands of agomelatine
If you are starting agomelatine, see 10 things you should know about antidepressants.
For more information
- Starting, switching and stopping antidepressants
- Managing side effects of antidepressants
- Psychological therapies
The consumer medicine information (CMI) for your brand of agomelatine is available from our website or a pharmacist. The CMI includes:
- how to take this medicine
- what to do if you forget to take it
- if you take too much (overdose)
- things you must and must not do while taking this medicine
- signs of severe reactions and what to do.
- Rossi S, ed. eAMH [online]. Adelaide: Australian Medicines Handbook, 2012. www.amh.net.au. (Accessed 9 February 2012).
- Servier Laboratories (Aust) Pty Ltd. Valdoxan consumer medicine information. July 2010.
- Servier Laboratories (Aust) Pty Ltd. Valdoxan product information. 8 July 2011. www.ebs.tga.gov.au/ebs/picmi/picmirepository.nsf/pdf?OpenAgent&id=CP-2010-PI-07273-3 (Accessed 22 March 2012).
- Therapeutic Goods Administration. Australian Public Assessment Report for agomelatine. Canberra: TGA, 2010. www.tga.gov.au/pdf/auspar/auspar-valdoxan.pdf (Accessed 7 March 2012).